Advertisement!
Author Information Pack
Editorial Board
Submit article
Special Issue
Editor's selection process
Join as Reviewer/Editor
List of Reviewer
Indexing Information
Most popular articles
Purchase Single Articles
Archive
Free Online Access
Current Issue
Recommend this journal to your library
Advertiser
Accepted Articles
Search Articles
Email Alerts
FAQ
Contact Us
Journal of Cardiovascular Medicine and Surgery

Volume  4, Issue 1, January - March 2018, Pages 50-56
 

Original Article

Retroperitoneal Fibrosis Masquerading as Malignancy: A Clinical Dilemma-Case Report

P.M. Ponoth, A.J. Ruturi, S.N.K. Waweru, S.K. Panchal, A.K. Gikonyo, A.W. Kanyua, O.A Morara,

1 Consultant, Department of Thoracic and Cardiovascular surgery 3 Department of Urology 4 Department of Cardiac Anaesthesia 5 Department of Cardiology 6Department of Pathology, The Karen Hospital, Nairobi, Kenya. 2 Department of Thoracic and Cardiovascular surgery, The Aga Khan University, Nairobi, Kenya. 7 Department of Thoracic and cardiovascular surgery, Kenyatta National Hospital (KNH), University of Nairobi, Nairobi, Kenya.

Choose an option to locate / access this Article:
90 days Access
Check if you have access through your login credentials.        PDF      |
|

Open Access: View PDF

DOI: http://dx.doi.org/10.21088/jcms.2454.7123.4118.8

Abstract

Retroperitoneal fibrosis is a rare vascular connective tissue disease of unknown aetiology, typically presenting as inflammation within the retroperitoneum with the resultant mass effect of the pathological processes involved compress the organs in the retroperitoneum: Kidneys, ureter, aorta and pancreas. The disease was first described by John Kelso Ormond in 1948 on a patient who presented with bilateral ureteral obstruction secondary to an inflammatory retroperitoneal process [2,3]. Its incidence is at 1.38 cases per 100,000 [1]. It has a male predominance of between 1.6 to 3 fold [1,7]. There have been associations of retroperitoneal fibrosis with various autoimmune conditions.Immunosuppressive treatment modalities have been effective on its control and management thus indirectly inferring to an autoimmune process as a key factor behind its pathophysiology [4, 5]. Radiological diagnosis through CT remains a gold standard with biopsy being a controversial option of obtaining diagnosis [5, 17-21]. Main stay treatment has been use of glucocorticoids as 1st line, with the disease modifying anti-rheumatic drugs (DMARDS) as a second option where the disease has been found to be steroid resistant [6]. For the scope of this paper, we will describe a case managed at the Karen hospital in Nairobi, Kenya in September 2017.

 


Keywords : Retroperitoneal Fibrosis; Lymphoma; Retroperitoneal Mass. 
Corresponding Author : Premanand Ponoth Chief-Cardiothoracic & Vascular Surgery, Hon. Prof. the Tamil Nadu MGR Medical University, Chennai, Dr. Kamakshi Memorial Hospital & Prasanth Super Speciality Hospital Chennai, Tamil Nadu 600100, India. and Consultant at The Karen Hospita